Literature DB >> 12601859

[Preparation of interferon-alpha-containing liposomes by the powder bed grinding method]

Zhi-Wei Ye1, Qiao-Hong Hu, Wen-Quan Liang.   

Abstract

OBJECTIVE: To investigate a nwe, simple technique for preparation of interferon-alpha-liposomes, which may be suitable for industrial use. METHODS The uniform design coupled with computerized optimization was utilized to screen the formulation and preparation procedure of interferon-alpha-liposomes. Pro-liposomes were prepared by the powder bed grinding method and combined with interferon-alpha-solution to form interferon-alpha-liposomes. Liposome size was determined by the particle size analyzer. Free interferon-alpha and interferon-alpha-liposome were separated by gel filtration. Then the recovered activity of interferon-alpha was analyzed by enzyme-linked immunosorbent assay. RESULTS The result demonstrated that the best interferon-alpha-liposome formulation was as follows: the protectant was sorbitol; weight ratio of protectant to lipid was 5:1; weight ratio of octadecytamin to lipid was 1:9; weight ratio of sobey phosphatidylcholine to cholesterol was 9:1 respectively. Interferon-alpha-liposome size determined by the particle size analyzer was 80.8+/-36 nm and the encapsulation efficiency was 59.0+/-3.3%. CONCLUSION The powder bed grinding method can be used to prepare pro-liposomes which can be easily combined with interferon-alpha-solution to form interferon-alpha-liposomes.

Entities:  

Year:  2002        PMID: 12601859

Source DB:  PubMed          Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban        ISSN: 1008-9292


  2 in total

1.  Formulation Development and in vitro Characterization of Proliposomes for Topical Delivery of Aceclofenac.

Authors:  Vandana Gupta; Ashok K Barupal; Suman Ramteke
Journal:  Indian J Pharm Sci       Date:  2008-11       Impact factor: 0.975

Review 2.  Toll-Like Receptors and Relevant Emerging Therapeutics with Reference to Delivery Methods.

Authors:  Nasir Javaid; Farzana Yasmeen; Sangdun Choi
Journal:  Pharmaceutics       Date:  2019-09-01       Impact factor: 6.321

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.